NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1957.30 10.10 (0.52%)

490.9K NSE+BSE Volume

NSE 09 Sep, 2025 3:42 PM (IST)

89,400.6

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

US FDA Observation

Lupin gets 2 observations from the US FDA following a PAI at its Aurangabad manufacturing facility See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

13 Feb 2025

1957.30

0.52%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Lupin Ltd. is trading below its 100 day SMA of 1969.9

Lupin Ltd.

13 Feb 2025

1957.30

0.52%

LUPIN LTD

Buy: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Lupin Ltd. is trading above its 50 day SMA of 1935.5

Lupin Ltd.

30 Dec 2024

1957.30

0.52%

Delay in approval for Amneal's gProAir an unexpected positive

Buy: Lupin Ltd.

Emkay

In Teva’s litigation with Amneal which blocked Amneal’s launch of gProAir, the US Court of Appeals had recently asked Teva to delist its patents in contention. While the ruling was expected to clear the way for Amneal’s launch of gProAir, Teva has now filed a petition seeking an en banc rehearing.

Sharekhan released a Buy report for Lupin Ltd. with a price target of 2400.0 on 21 Aug, 2025.

Lupin Ltd.

16 Dec 2024

1957.30

0.52%

Lupin (BUY): Reduction in in-licence portfolio to increase margins

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's domestic region in-licence portfolio fell from 15% in Q2FY24 to 12% in Q2FY25 and is expected to reduce further to ~10% by FY26

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

11 Nov 2024

1957.30

0.52%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,600/share.

Sharekhan released a Buy report for Lupin Ltd. with a price target of 2400.0 on 21 Aug, 2025.

Lupin Ltd.

10 Nov 2024

1957.30

0.52%

Superlative margin performance; US reversal likely in 3Q

Buy: Lupin Ltd.

Target

Emkay

Lupin’s 2QFY25 EBITDA/Adj PAT were 18%/26% ahead of our estimates (the magnitude of beat was broadly similar vs street estimates).

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

09 Nov 2024, 12:00AM

1957.30

0.52%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

08 Aug 2024, 12:00AM

1957.30

0.52%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

07 Aug 2024

1957.30

0.52%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.